Small-molecule inhibitors/modulators of amyloid-β peptide aggregation and toxicity for the treatment of Alzheimer's disease: a patent review (2010 – 2012)

Bibliography

• Walker LC, LeVine H. The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly. Mol Neurobiol 2000;21(1-2):83-95
   PubMed Web of Science ®Google Scholar
• Hardy J. Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: 'permissive templating' as a general mechanism underlying neurodegeneration. Biochem Soc Trans 2005;33(Pt 4):578-81
   PubMedGoogle Scholar
• Ferri CP, Prince M, Brayne C, Global prevalence of dementia: a Delphi consensus study. Lancet 2005;366(9503):2112-17
   PubMed Web of Science ®Google Scholar
• Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement 2010;6(2):98-103
   PubMed Web of Science ®Google Scholar
• Glenner GG, Wong CW, Quaranta V, Eanes ED. The amyloid deposits in Alzheimer's disease: their nature and pathogenesis. Appl Pathol 1984;2(6):357-69
   PubMedGoogle Scholar
• Burdick D, Soreghan B, Kwon M, Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs. J Biol Chem 1992;267(1):546-54
   PubMed Web of Science ®Google Scholar
• Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 1992;256(5054):184-5
   PubMed Web of Science ®Google Scholar
• Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6(4):487-98
   PubMed Web of Science ®Google Scholar
• Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297(5580):353-6
   PubMed Web of Science ®Google Scholar
• Doody RS. Therapeutic standards in Alzheimer disease. Alzheimer Dis Assoc Disord 1999;13(Suppl 2):S20-6
   PubMed Web of Science ®Google Scholar
• Soto C, Sigurdsson EM, Morelli L, Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. Nat Med 1998;4(7):822-6
   PubMed Web of Science ®Google Scholar
• Ghanta J, Shen CL, Kiessling LL, Murphy RM. A strategy for designing inhibitors of beta-amyloid toxicity. J Biol Chem 1996;271(47):29525-8
   PubMed Web of Science ®Google Scholar
• Citron M. Strategies for disease modification in Alzheimer's disease. Nat Rev Neurosci 2004;5(9):677-85
   PubMed Web of Science ®Google Scholar
• Murphy RM. Kinetics of amyloid formation and membrane interaction with amyloidogenic proteins. Biochim Biophys Acta 2007;1768(8):1923-34
   PubMed Web of Science ®Google Scholar
• Pellarin R, Caflisch A. Interpreting the aggregation kinetics of amyloid peptides. J Mol Biol 2006;360(4):882-92
   PubMed Web of Science ®Google Scholar
• Walsh DM, Klyubin I, Fadeeva JV, Amyloid-beta oligomers: their production, toxicity and therapeutic inhibition. Biochem Soc Trans 2002;30(4):552-7
   PubMedGoogle Scholar
• Lambert MP, Barlow AK, Chromy BA, Diffusible, nonfibrillar ligands derived from A beta(1-42) are potent central nervous system neurotoxins. Proc Natl Acad Sci USA 1998;95(11):6448-53
   PubMed Web of Science ®Google Scholar
• Cleary JP, Walsh DM, Hofmeister JJ, Natural oligomers of the amyloid-protein specifically disrupt cognitive function. Nat Neurosci 2005;8(1):79-84
   PubMed Web of Science ®Google Scholar
• Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 2007;101(5):1172-84
   PubMed Web of Science ®Google Scholar
• Walsh DM, Hartley DM, Kusumoto Y, Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 1999;274(36):25945-52
   PubMed Web of Science ®Google Scholar
• Walsh DM, Lomakin A, Benedek GB, Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem 1997;272(35):22364-72
   PubMed Web of Science ®Google Scholar
• Harper JD, Wong SS, Lieber CM, Lansbury PT. Observation of metastable Abeta amyloid protofibrils by atomic force microscopy. Chem Biol 1997;4(2):119-25
   PubMedGoogle Scholar
• Chromy BA, Nowak RJ, Lambert MP, Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 2003;42(44):12749-60
   PubMed Web of Science ®Google Scholar
• Walsh DM, Klyubin I, Fadeeva JV, Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416(6880):535-9
   PubMed Web of Science ®Google Scholar
• Selkoe DJ, Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 2003;43:545-84
   PubMed Web of Science ®Google Scholar
• Ma B, Nussinov R. Simulations as analytical tools to understand protein aggregation and predict amyloid conformation. Curr Opin Chem Biol 2006;10(5):445-52
   PubMed Web of Science ®Google Scholar
• Sunde M, Blake C. The structure of amyloid fibrils by electron microscopy and X-ray diffraction. Adv Protein Chem 1997;50:123-59
   PubMedGoogle Scholar
• Fandrich M, Schmidt M, Grigorieff N. Recent progress in understanding Alzheimer's beta-amyloid structures. Trends Biochem Sci 2011;36(6):338-45
   PubMed Web of Science ®Google Scholar
• Maji SK, Ogorzalek Loo RR, Inayathullah M, Amino acid position-specific contributions to amyloid beta-protein oligomerization. J Biol Chem 2009;284(35):23580-91
   PubMed Web of Science ®Google Scholar
• Tjernberg LO, Naslund J, Lindqvist F, Arrest of beta-amyloid fibril formation by a pentapeptide ligand. J Biol Chem 1996;271(15):8545-8
   PubMed Web of Science ®Google Scholar
• Liao MQ, Tzeng YJ, Chang LY, The correlation between neurotoxicity, aggregative ability and secondary structure studied by sequence truncated Abeta peptides. FEBS Lett 2007;581(6):1161-5
   PubMed Web of Science ®Google Scholar
• Tjernberg LO, Lilliehook C, Callaway DJ, Controlling amyloid beta-peptide fibril formation with protease-stable ligands. J Biol Chem 1997;272(19):12601-5
   PubMed Web of Science ®Google Scholar
• Makin OS, Atkins E, Sikorski P, Molecular basis for amyloid fibril formation and stability. Proc Natl Acad Sci U S A 2005;102(2):315-20
   PubMed Web of Science ®Google Scholar
• Usui K, Hulleman JD, Paulsson JF, Site-specific modification of Alzheimer's peptides by cholesterol oxidation products enhances aggregation energetics and neurotoxicity. Proc Natl Acad Sci U S A 2009;106(44):18563-8
   PubMed Web of Science ®Google Scholar
• Cordy JM, Hooper NM, Turner AJ. The involvement of lipid rafts in Alzheimer's disease. Mol Membr Biol 2006;23(1):111-22
   PubMed Web of Science ®Google Scholar
• Malchiodi-Albedi F, Contrusciere V, Raggi C, Lipid raft disruption protects mature neurons against amyloid oligomer toxicity. Biochim Biophys Acta 2010;1802(4):406-15
   PubMed Web of Science ®Google Scholar
• Gervais F, Paquette J, Morissette C, Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging 2007;28(4):537-47
   PubMed Web of Science ®Google Scholar
• Aisen PS, Saumier D, Briand R, A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology 2006;67(10):1757-63
   PubMed Web of Science ®Google Scholar
• McLaurin J, Golomb R, Jurewicz A, Inositol stereoisomers stabilize an oligomeric aggregate of Alzheimer amyloid beta peptide and inhibit abeta -induced toxicity. J Biol Chem 2000;275(24):18495-502
   PubMed Web of Science ®Google Scholar
• McLaurin J, Kierstead ME, Brown ME, Cyclohexanehexol inhibitors of Abeta aggregation prevent and reverse Alzheimer phenotype in a mouse model. Nat Med 2006;12(7):801-8
   PubMed Web of Science ®Google Scholar
• Ehrnhoefer DE, Bieschke J, Boeddrich A, EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat Struct Mol Biol 2008;15(6):558-66
   PubMed Web of Science ®Google Scholar
• Riviere C, Papastamoulis Y, Fortin P-Y, New stilbene dimers against amyloid fibril formation. Bioorg Med Chem Lett 2010;20(11):3441-3
   PubMed Web of Science ®Google Scholar
• Ge J-F, Qiao J-P, Qi C-C, The binding of resveratrol to monomer and fibril amyloid beta. Neurochem Int 2012;61(7):1192-201
   PubMed Web of Science ®Google Scholar
• Granzotto A, Zatta P. Resveratrol acts not through anti-aggregative pathways but mainly via its scavenging properties against Abeta and Abeta-metal complexes toxicity. PLoS ONE 2011;6(6):e21565-e65
   PubMed Web of Science ®Google Scholar
• Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J Neurosci Res 2004;75(6):742-50
   PubMed Web of Science ®Google Scholar
• Lim GP, Chu T, Yang F, The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21(21):8370-7
   PubMed Web of Science ®Google Scholar
• Kim H, Park BS, Lee KG, Effects of naturally occurring compounds on fibril formation and oxidative stress of beta-amyloid. J Agric Food Chem 2005;53(22):8537-41
   PubMed Web of Science ®Google Scholar
• Reinke AA, Gestwicki JE. Structure-activity relationships of amyloid beta-aggregation inhibitors based on curcumin: influence of linker length and flexibility. Chem Biol Drug Des 2007;70(3):206-15
   PubMed Web of Science ®Google Scholar
• Harvey AL. Natural products in drug discovery. Drug Discov Today 2008;13(19-20):894-901
   PubMed Web of Science ®Google Scholar
• Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod 2003;66(7):1022-37
   PubMed Web of Science ®Google Scholar
• Paterson I, Anderson EA. Chemistry. The renaissance of natural products as drug candidates. Science 2005;310(5747):451-3
   PubMed Web of Science ®Google Scholar
• Zhang S, Guo TL. inventors; Virginia Commonwealth University, USA. assignee. Bivalent multifunctional ligands targeting abeta oligomers as treatment for Alzheimer's disease patent. WO2012012257A2; 2012
   Google Scholar
• Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23(1A):363-98
   PubMed Web of Science ®Google Scholar
• Antimisiari S, Mourtas S, Niaraki A, inventors; University of Patras, Greece; Universita degli Studi di Milano - Bicocca; Antimisiari Sofia. assignee. Curcumin derivatives with improved physicochemical properties and nanoliposomes surface-decorated with the derivatives with very high affinity for amyloid-beta 1-42 peptide patent. EP2436673A1; 2012
   Google Scholar
• Scherzer R, Gazit E, Segal D. inventors; Ramot at Tel Aviv University Ltd., Israel. assignee. Naphthoquinone derivatives useful for prevention of amyloid deposits and treatment of diseases involving amyloidogenesis patent. WO2010026592A1; 2010
   Google Scholar
• Frydman-Marom A, Rechter M, Shefler I, Cognitive-performance recovery of Alzheimer's disease model mice by modulation of early soluble amyloidal assemblies. Angew Chem Int Ed Engl 2009;48(11):1981-6
   PubMed Web of Science ®Google Scholar
• Necula M, Kayed R, Milton S, Glabe CG. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem 2007;282(14):10311-24
   PubMed Web of Science ®Google Scholar
• Giuffrida ML, Caraci F, Pignataro B, Beta-amyloid monomers are neuroprotective. J Neurosci 2009;29(34):10582-7
   PubMed Web of Science ®Google Scholar
• Shin KJ, Roh EJ, Lee YS. inventors; Korea Institute of Science and Technology, S. Korea. assignee. Preparation of bis(styryl)pyrimidine derivatives and analogs for use as beta amyloid inhibitors patent. US20100190803A1; 2010
   Google Scholar
• Ray M, Pal R, Singh S, Khanna NM. inventors; Council of Scientific and Industrial Research, India. assignee. A composition containing Curcuma extracts for treating neurocerebrovascular disorders patent. WO2003051380A2; 2003
   Google Scholar
• Anand P, Singh B, Jaggi AS, Singh N. Mast cells: an expanding pathophysiological role from allergy to other disorders. Naunyn Schmiedebergs Arch Pharmacol 2012;385(7):657-70
   PubMed Web of Science ®Google Scholar
• Elmaleh DR, Shoup T. inventors; The General Hospital Corp., USA. assignee. Preparation of cromolyn derivatives as imaging and pharmaceutical agents patent. WO2010088455A2; 2010
   Google Scholar
• Pene F, Courtine E, Cariou A, Mira JP. Toward theragnostics. Crit Care Med 2009;37(1 Suppl):S50-8
   PubMed Web of Science ®Google Scholar
• Jimenez C, Riguera R. Phenylethanoid glycosides in plants: structure and biological activity. Nat Prod Rep 1994;11(6):591-606
   PubMed Web of Science ®Google Scholar
• Lin H-C, Su M-H, Huang Y-M, Tang J-J. inventors; Sinphar Tian-Li Pharmaceutical Co., Ltd., Peop. Rep. China. assignee. Use of isoacteoside or pharmaceutically acceptable salt thereof patent. WO2011157059A1; 2011
   Google Scholar
• Suzuki S, Maruyama S, Sato W, Geranylgeranylacetone ameliorates ischemic acute renal failure via induction of Hsp70. Kidney Int 2005;67(6):2210-20
   PubMed Web of Science ®Google Scholar
• Barres BA, Nakayama N, Serizawa H, Argade AB. inventors; Coyote Pharmaceuticals, Inc., USA. assignee. Preparation of geranylgeranyl acetone isomers for treating neurodegenerative diseases patent. WO2012031028A2; 2012
   Google Scholar
• Kim DJ, Yoo KH, Byun JH, inventors; Korea Institute of Science and Technology, S. Korea; Hanmi Pharm. Co., Ltd. assignee. Preparation of benzofuran derivatives as beta-amyloid fibril formation inhibitors patent. WO2009151299A2; 2009
   Google Scholar
• Kudo Y, Suzuki M, Suemoto T, inventors; BF Research Institute, Inc., Japan. assignee. Preparation of thiazole and oxazole derivatives as probe for amyloid accumulation diseases and as staining agents for neurofibrillary change patent. WO2005016888A1; 2005
   Google Scholar
• Klunk WE, Mathis CA Jr, Wang Y. inventors; University of Pittsburgh, USA. assignee. Preparation of thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition patent. WO2002016333A2; 2002
   Google Scholar
• Petkova AT, Ishii Y, Balbach JJ, A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci U S A 2002;99(26):16742-7
   PubMed Web of Science ®Google Scholar
• Kroth H, Hamel C, Benderitter P, inventors; AC Immune S.A., Switz. assignee. Preparation of 7-azaindole, indole, and carbazole compounds for the treatment of diseases associated with amyloid or amyloid-like proteins patent. WO2011128455A1; 2011
   Google Scholar
• Kroth H, Hamel C, Benderitter P, inventors; AC Immune S.A., Switz. assignee. Preparation of novel 3,5-diaminopyridine compounds for the treatment of diseases associated with amyloid or amyloid-like proteins patent. EP2377860A1; 2011
   Google Scholar
• Reed MA, Yadav A, Banfield SC, Barden CJ. inventors; Treventis Corp., USA. assignee. Preparation of amino substituted biaryl compounds as anti-amyloid agents patent. WO2012119035A1; 2012
   Google Scholar
• Nakagami Y, Nishimura S, Murasugi T, A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment of long-term potentiation in vitro. Br J Pharmacol 2002;137(5):676-82
   PubMed Web of Science ®Google Scholar
• Meguro M, Oda T, Nakagami Y, inventors; Sankyo Co., Ltd, Japan. assignee. Preparation of aryldiamine derivatives as amyloid protein fibrosis inhibitors for treatment of Alzheimer's disease patent. WO2003045923A1; 2003
   Google Scholar
• Horwell D, Scopes D. inventors; Senexis Ltd, UK. assignee. Preparation of phenoxypyrimidinylaminobenzonitriles useful in treatment of amyloid-related diseases patent. WO2011144577A1; 2011
   Google Scholar
• Horwell DC, Scopes DIC. inventors; Senexis Ltd, UK. assignee. Preparation of novel heterocyclic compounds useful in treatment of amyloid-related diseases patent. WO2011144578A1; 2011
   Google Scholar
• Aasberg P, Johansson L, Herland A. inventors; BioChromix Pharma AB, Swed. assignee. Preparation of thiophene derivatives for treatment of proteopathy patent. WO2010044743A1; 2010
   Google Scholar
• Kirsten CN, Schrader TH. Intermolecular beta-sheet stabilization with aminopyrazoles. J Am Chem Soc 1997;119(50):12061-8
   Web of Science ®Google Scholar
• Schrader T, Kirsten C. Intermolecular stabilisation of the beta-sheet conformation in dipeptides. Chem Commun 1996;17:2089-90
   Google Scholar
• Schrader T, Riesner D, Nagel-Steger L, inventors; Philipps-Universitaet Marburg, Germany. assignee. Preparation of trimeric, water-soluble aminopyrazole compounds, particularly aminopyrazole peptide conjugates, for prevention and treatment of neurodegenerative diseases patent. WO2007112922A1; 2007
   Google Scholar
• Schrader T, Hochdoerffer K, Marz-Berberich J, inventors; Universitaet Duisburg-Essen, Germany. assignee. Preparation of trimeric aminopyrazole compounds, particularly peptide conjugates, for the treatment of diseases related to protein misfolding patent. WO2011050864A1; 2011
   Google Scholar
• Barden CJ, Carter MD, Reed MA, inventors; Treventis Corp., USA. assignee. Compositions and methods of treating amyloid disease patent. WO2010025375A1; 2010
   Google Scholar
• Esposito LA, Hudson FM, Lake T, inventors; Proteotech Inc., USA. assignee. Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies patent. WO2010039308A1; 2010
   Google Scholar
• Look GC, Schultz L, Polozov AM, inventors Acumen Pharmaceuticals, Inc., USA. assignee. Methods of inhibiting the formation of amyloid-beta diffusible ligands using acylhydrazide compounds patent. US20110098309A1; 2011
   Google Scholar
• Klunk WE, Debnath ML, Pettegrew JW. Development of small molecule probes for the beta-amyloid protein of Alzheimer's disease. Neurobiol Aging 1994;15(6):691-8
   PubMed Web of Science ®Google Scholar
• Wanker E, Wiglenda T, Babila JT, inventors; Max-Delbrueck-Centrum fuer Molekulare Medizin, Germany. assignee. Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates patent. EP2368558A1; 2011
   Google Scholar
• Wanker E, Wiglenda T, Babila JT, inventors; Max-Delbrueck-Centrum fuer Molekulare Medizin, Germany. assignee. Azo compounds reducing formation and toxicity of amyloid beta aggregation intermediates patent. WO2011117305A1; 2011
   Google Scholar
• Bitan G, Shanmugam A, Lomakin A, inventors; University of California, USA; Universitat Duisburg-Essen; Massachusetts Institute of Technology; Department of Veterans Affairs. assignee. Molecular tweezers for the treatment of amyloid-related diseases patent. WO2010102248A2; 2010
   Google Scholar
• Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007;450(7172):1001-9
   PubMed Web of Science ®Google Scholar
• Necula M, Breydo L, Milton S, Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry 2007;46(30):8850-60
   PubMed Web of Science ®Google Scholar